Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

27.03.2017 | case report

Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma

verfasst von: Sonja Burgstaller, MD, Josef Thaler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Summary

The patient presented here was diagnosed with multifocal primary cutaneous anaplastic large-cell lymphoma at the age of 80 years. Initially, he received chemotherapy plus prednisolone, which had to be discontinued due to toxicity. Treatment with brentuximab vedotin was then commenced, which promoted reductions in skin lesions of the patient, and was well tolerated. New lesions occurred 6 months after the start of brentuximab vedotin therapy, but were successfully controlled with irradiation. The patient experienced sustained disease control with ongoing brentuximab vedotin administration for more than 1 year. His quality of life is not compromised by this treatment in spite of his advanced age.
Vorheriger Artikel Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia
Nächster Artikel Highlights from the 2017 St. Gallen Breast Cancer Consensus
Literatur
1.
Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organisation of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–22.CrossRefPubMed
2.
Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73.CrossRefPubMedPubMedCentral
3.
Cuneo A, Castoldi GL. Primary cutaneous CD30+ anaplastic large-cell lymphoma. Atlas Genet Cytogenet Oncol Haematol. 2005;9(3):244–5.
4.
Weng WK, Armstrong R, Arai S, et al. Minimal residual disease monitoring with high-throughput sequencing of T‑cell receptors in cutaneous T‑cell lymphoma. Sci Transl Med. 2013;5(214):214ra171.CrossRefPubMed
5.
Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490–5.PubMedPubMedCentral
6.
Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–66.CrossRefPubMed
7.
Rozati S, Kim YH. Experimental treatment strategies in primary cutaneous T‑cell lymphomas. Curr Opin Oncol. 2016;28(2):166–71.CrossRefPubMed
8.
Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012;11(1):19–20.CrossRefPubMed
9.
Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65.CrossRefPubMed
10.
Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–35.CrossRefPubMedPubMedCentral
11.
Duvic M, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T‑cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65.CrossRefPubMedPubMedCentral
12.
Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression levels: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–8.CrossRefPubMedPubMedCentral
Metadaten
Titel
Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
verfasst von
Sonja Burgstaller, MD
Josef Thaler
Publikationsdatum
27.03.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0325-5

Weitere Artikel der Ausgabe 3/2017

Renal insufficiency in patients with multiple myeloma

  • review

Chemotherapies and future directions in metastatic colorectal cancer

  • short review

New diagnostic tools for breast cancer

  • Open Access
  • short review

Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia

  • review

Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer

  • Open Access
  • short review

What’s new in chemotherapy for non-small cell lung cancer?

  • short review